title: Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?
authors.affiliation: a Division of Hematology/Oncology, Feinberg School of Medicine , Northwestern University, Robert H. Lurie Comprehensive Cancer Center , Chicago , IL , USA.
authors.forename: Jason B
authors.initials: JB
authors.lastname: Kaplan
authors.affiliation: a Division of Hematology/Oncology, Feinberg School of Medicine , Northwestern University, Robert H. Lurie Comprehensive Cancer Center , Chicago , IL , USA.|b Jesse Brown VA Medical Center , Chicago , IL , USA.
authors.forename: Leonidas C
authors.initials: LC
authors.lastname: Platanias
mesh_terms: D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D009154:Mutation / Q000187:drug effects; D047428:Protein Kinase Inhibitors
chemical_list: D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl